CB-5339

N/A

Report date: 2026/03/10 20:00:16
NME

Base Information

Drug NameCB-5339
Drug Alias NameCB-5339CB-5339 tosylate
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransitional endoplasmic reticulum ATPase inhibitors
TargetsTransitional endoplasmic reticulum ATPase
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesMultiple Myeloma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCleave
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteCasi Pharmaceuticals IncCleave Therapeutics Inc +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesMultiple Myeloma +[5] 
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A